Literature DB >> 9750028

Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein.

Y Sugiyama1, Y Kato, X Chu.   

Abstract

A frequent dose-limiting effect of irinotecan (CPT-11) is its gastrointestinal toxicity (diarrhea), which is thought to be related to biliary excretion of CPT-11 and its metabolites. Accordingly, we have investigated the mechanism of biliary excretion of these compounds. In vivo pharmacokinetic studies revealed that the biliary excretion of the four anionic forms of CPT-11 and its metabolites was reduced in Eisai hyperbilirubinemic rats, which carry a mutation of the hepatic canalicular multispecific organic anion transporter (cMOAT) gene. The protein encoded by this gene is expressed on the bile canalicular membrane and is responsible for the transport of organic anions into bile. Detailed analysis using isolated liver bile canalicular membrane vesicles to identify transport systems showed that cMOAT is responsible for biliary excretion of the low-affinity component of the carboxylate form of CPT-11 and the high-affinity component of both the lactone and carboxylate forms of SN-38 glucuronide. The carboxylate form of SN-38 is transported by cMOAT alone. Transport of the high-affinity component of CPT-11 was inhibited by verapamil and PSC-833, but their effect on the transport of its low-affinity component was minimal. In addition, ATP dependence in the uptake of CPT-11 by membrane vesicles obtained from a P-glycoprotein (P-gp)-overexpressing cell line was observed. Thus P-gp may be responsible for transport of the high-affinity component of the carboxylate form of CPT-11.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9750028     DOI: 10.1007/s002800051078

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  23 in total

Review 1.  The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.

Authors:  H A Bardelmeijer; O van Tellingen; J H Schellens; J H Beijnen
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

2.  Metabolic pathways of the camptothecin analog AR-67.

Authors:  Jamie Horn; Marta Milewska; Susanne M Arnold; Markos Leggas
Journal:  Drug Metab Dispos       Date:  2010-12-28       Impact factor: 3.922

Review 3.  A perspective on efflux transport proteins in the liver.

Authors:  K Köck; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2012-09-05       Impact factor: 6.875

4.  MRP3, an organic anion transporter able to transport anti-cancer drugs.

Authors:  M Kool; M van der Linden; M de Haas; G L Scheffer; J M de Vree; A J Smith; G Jansen; G J Peters; N Ponne; R J Scheper; R P Elferink; F Baas; P Borst
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

Review 5.  Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.

Authors:  Tessa M Bosch; Irma Meijerman; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice.

Authors:  Michael Tagen; Yanli Zhuang; Fan Zhang; K Elaine Harstead; Jun Shen; Paula Schaiquevich; Charles H Fraga; John C Panetta; Christopher M Waters; Clinton F Stewart
Journal:  Drug Metab Lett       Date:  2010-12

7.  Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.

Authors:  D J Crona; J Ramirez; W Qiao; A-J de Graan; M J Ratain; R H N van Schaik; R H J Mathijssen; G L Rosner; F Innocenti
Journal:  Pharmacogenomics J       Date:  2015-04-14       Impact factor: 3.550

8.  Development and validation of an UPLC-MS/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: Application to a pharmacokinetic study of irinotecan in rats.

Authors:  Sumit Basu; Min Zeng; Taijun Yin; Song Gao; Ming Hu
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-02-09       Impact factor: 3.205

Review 9.  Contribution of tumoral and host solute carriers to clinical drug response.

Authors:  Jason A Sprowl; Torben S Mikkelsen; Hugh Giovinazzo; Alex Sparreboom
Journal:  Drug Resist Updat       Date:  2012-03-28       Impact factor: 18.500

Review 10.  The role of human carboxylesterases in drug metabolism: have we overlooked their importance?

Authors:  S Casey Laizure; Vanessa Herring; Zheyi Hu; Kevin Witbrodt; Robert B Parker
Journal:  Pharmacotherapy       Date:  2013-02       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.